You may know BRCA1 and BRCA2, but other inherited genes, including HOXB13, ATM, CHEK2 and MSH2, can also increase your risk of prostate cancer. For you, each gene can have different implications for cancer risk, treatment relevance and your family’s health.
If you have prostate cancer or a strong family history, your doctor can help you decide whether genetic testing is appropriate. Understanding your results can help guide your care and identify whether your relatives may benefit from genetic advice.
Why Are Genes Other Than BRCA Important in Prostate Cancer?
You may know BRCA2 as an inherited prostate cancer risk gene, but others, including HOXB13, ATM, CHEK2 and MSH2, can also increase your risk. For you, the implications differ by gene: HOXB13 mainly informs inherited susceptibility, while pathogenic BRCA2 and ATM variants have stronger evidence linking them with aggressive prostate cancer.
If you have a family history of prostate cancer, genetic testing may help clarify your inherited risk. Your doctor can explain what your results mean for your treatment and whether your relatives may benefit from genetic advice.
UK Guidance Note
The current NHS England R430 inherited-prostate-cancer panel includes BRCA1, BRCA2, PALB2, MLH1, MSH2, MSH6, ATM and CHEK2. HOXB13 is an established hereditary prostate-cancer susceptibility gene, but it is not currently listed on the standard R430 panel.
This means a gene can be scientifically associated with prostate-cancer risk without automatically being part of the routine NHS test offered under a specific clinical indication. Broader panels may be available through other pathways, specialist genetics services or research studies.
What Is HOXB13?
HOXB13 is a gene that helps regulate the development and function of your prostate. Certain inherited variants, particularly G84E, can increase your risk of developing prostate cancer, especially if you have a family history of the disease.
Unlike BRCA2, HOXB13 is not primarily involved in DNA repair, so its implications for targeted treatment are different. If you carry a HOXB13 variant, your doctor can explain what it means for your personal risk and whether additional screening or genetic advice may be appropriate for you.
How Much Does HOXB13 Increase Prostate Cancer Risk?
If you carry the HOXB13 G84E variant, your risk of developing prostate cancer may be around three times higher than someone without it. However, your actual risk depends on factors such as your family history and ancestry.
If you have several close relatives diagnosed with prostate cancer, particularly at younger ages, your risk may be higher. These estimates mainly apply to G84E, so your doctor should interpret your genetic results alongside your personal and family history.
Evidence Note
The 2025 Million Veteran Program analysis included 1,660 HOXB13 G84E carriers among more than 592,000 men. G84E was associated with higher overall prostate-cancer risk, metastatic prostate-cancer risk and prostate-cancer-specific mortality at the population level.
However, among men who developed prostate cancer, carriers had similar Gleason-score distributions and comparable rates of metastatic and castration-resistant disease to non-carriers. The authors concluded that G84E increases the likelihood of developing prostate cancer but does not clearly make the cancer itself biologically more aggressive.
Does HOXB13 Cause More Aggressive Prostate Cancer?

If you carry a HOXB13 variant, your risk of developing prostate cancer is higher, but this does not necessarily mean your cancer will be more aggressive. Research suggests that some carriers may develop prostate cancer at a younger age, although evidence linking HOXB13 directly to more aggressive disease remains mixed.
If you have a HOXB13 variant, your doctor will consider your genetic results alongside your family history and other clinical findings. Unlike BRCA2, HOXB13 is primarily recognised as an inherited risk gene, so you should not assume that carrying it automatically predicts how your cancer will behave.
Is HOXB13 the Same Kind of Gene as BRCA2?
No. Both genes can increase your risk of prostate cancer, but they work differently. BRCA2 helps repair damaged DNA, and changes in this gene can make some cancers vulnerable to targeted treatments such as PARP inhibitors. HOXB13 mainly helps regulate prostate development and cell function.
If you carry a HOXB13 variant, it may help explain your inherited cancer risk, but it does not automatically make you eligible for PARP inhibitors. Your doctor can explain what your specific genetic result means for your care and whether your relatives may benefit from genetic advice.
What Is ATM and How Is It Linked to Prostate Cancer?
ATM is a gene involved in helping your cells detect and respond to DNA damage. Certain inherited ATM variants can be relevant to prostate cancer risk.
- DNA-damage response: ATM helps your cells recognise and respond when DNA has been damaged.
- Inherited risk: A pathogenic or likely pathogenic ATM variant can increase your risk of developing prostate cancer.
- Cancer behaviour: Research has linked some ATM variants with a higher likelihood of more aggressive disease.
- Treatment needs separate assessment: Having an ATM variant does not automatically mean targeted treatments such as PARP inhibitors will be suitable.
Your doctor can interpret the ATM result alongside your cancer features, treatment history and family history.
Does an ATM Variant Mean PARP Inhibitors Will Work?
No. If you have an ATM alteration, PARP inhibitors have shown substantially less benefit than in BRCA-altered prostate cancer. For you, treatment should therefore depend on the exact alteration, disease setting and approved indication.
If you have an ATM variant, your doctor will consider your cancer type, previous treatments and genetic test results before recommending therapy. Having an ATM alteration does not automatically mean PARP inhibitors are suitable for you, so treatment decisions should be based on evidence for your specific genetic finding.
What Is CHEK2?

CHEK2 helps your cells respond to DNA damage, and certain inherited variants can increase your risk of prostate cancer. The level of risk depends on the specific variant you carry, your family history and other genetic factors.
If you have a CHEK2 variant, it does not automatically mean you will develop prostate cancer. Your doctor can help you understand your individual risk and whether genetic counselling or additional screening may be appropriate for you.
Does CHEK2 Have the Same Treatment Implications as BRCA?
No. If you have a CHEK2 variant, you should not assume that PARP inhibitors will work as well as they do for cancers with BRCA1 or BRCA2 alterations. Research suggests that the evidence for PARP inhibitor benefit in CHEK2-altered prostate cancer remains limited.
Your CHEK2 result may be particularly useful for understanding your inherited cancer risk and whether your relatives need genetic advice. Your doctor can explain how your specific variant affects your treatment options, as different genes do not necessarily predict the same response to targeted therapies.
How Do These Inherited Genes Differ?
| Gene | Prostate-cancer risk | Aggressiveness evidence | Treatment relevance |
| HOXB13 | Strong risk association, especially G84E | Recent data do not show clearly more aggressive tumours | Mainly inherited-risk significance |
| BRCA2 | Strong | Stronger association with aggressive disease | Strongest PARP evidence |
| ATM | Increased risk | Evidence of more aggressive disease | PARP benefit less clear than BRCA |
| CHEK2 | Increased risk | Less clear aggressiveness signal | Limited PARP-response evidence |
| MSH2 | Increased risk through Lynch syndrome | dMMR can be associated with higher-risk disease | Tumour MMR/MSI status may be clinically relevant |
| PALB2 | Inherited-risk association less established than BRCA2 | Less established than BRCA2 | Possible PARP benefit, but evidence is less certain than for BRCA |
What Do Lynch Syndrome Genes Have to Do With Prostate Cancer?
Lynch syndrome is an inherited condition caused by changes in DNA repair genes, including MSH2, MSH6, MLH1 and PMS2. These changes can increase your risk of several cancers, including prostate cancer, with recent data showing particularly important prostate-cancer risk and tumour mismatch-repair findings in MSH2/EPCAM and MSH6 carriers.
If you carry a Lynch syndrome variant, your doctor can help you understand your cancer risks and whether you and your relatives may benefit from additional screening or genetic advice.
Can Lynch Syndrome Affect Prostate Cancer Treatment?
Yes. If your prostate cancer is mismatch-repair deficient or MSI-high, immunotherapy may be relevant in some international or trial settings. For you, NHS treatment availability depends on the specific indication, and a Lynch syndrome variant alone does not prove that your prostate tumour is dMMR.
Your doctor can explain what your results mean for treatment and whether you and your relatives need genetic advice or additional cancer screening.
What About PALB2 and Other Less Common Genes?

PALB2 helps repair damaged DNA, although its inherited prostate-cancer risk association is less established than BRCA2. For you, broader panels may also identify variants in other cancer-predisposition genes, but their prostate-specific relevance can vary.
If you consider genetic testing, your doctor can help choose a panel suited to your needs. Testing more genes does not always mean better results, as some findings may be uncertain or may not change your treatment or your family’s care.
Research Insight
A 2025 living meta-analysis combined 13 PARP-inhibitor trials involving 4,278 men with metastatic castration-resistant prostate cancer. The strongest and most consistent treatment benefit was seen in BRCA-altered disease.
The same analysis found much weaker or absent benefit in several non-BRCA subgroups, including ATM and CHEK2. This is why the phrase “DNA-repair mutation” is not specific enough when discussing treatment: the exact gene and alteration matter.
What Does It Mean if You Carry One of These Variants but Already Have Prostate Cancer?
If you already have prostate cancer, a genetic result may help explain your cancer risk, guide treatment options and identify risks for your family. For example, BRCA2 may influence targeted treatment, while HOXB13 can help explain a strong family history.
If you carry an autosomal-dominant pathogenic inherited variant, each biological child generally has a 50% chance of inheriting that specific variant. However, inheriting a variant does not mean a 50% chance of developing cancer. Your doctor can explain what your specific result means for your treatment and your relatives’ health.
What Should Relatives Do if HOXB13 or Another Risk Gene Is Found?
If you carry an inherited risk variant, your family members may also be at risk. A genetic counsellor can help you understand which relatives should consider testing for the specific variant found in your results.
If your male relative carries the familial variant, their genetics or clinical team can advise whether risk-based prostate assessment is appropriate for their age, family history and gene. If they test negative for your family’s known variant, they have not inherited the increased risk linked to that variant, although other risk factors may still affect them.
Clinical Tip
If a pathogenic inherited variant has been found in the family, relatives should ideally know the exact gene and variant, rather than simply being told that “prostate cancer is genetic”.
Predictive or cascade testing can then look specifically for that familial variant. A relative who tests negative for a known familial pathogenic variant has a very different result from someone who has had a broad panel test with no variant found.
Should Everyone With a Strong Prostate Cancer Family History Be Tested for HOXB13?
Not necessarily. If you have several relatives with prostate cancer, especially at younger ages, genetic testing may be worth considering. However, other cancers in your family may point towards genes such as BRCA1, BRCA2 or Lynch syndrome genes.
Your doctor or genetic counsellor can help choose a genetic panel that best fits your personal and family history. This helps you understand which inherited risks may be relevant and whether your results could change your care or your relatives’ screening.
What Should You Ask if Genetic Testing Identifies a Non-BRCA Variant?

If your genetic test identifies a non-BRCA variant, first ask whether it is classified as pathogenic, likely pathogenic or a variant of uncertain significance. Then ask what it means for your prostate cancer risk, treatment options and family history. Not every DNA-repair gene predicts the same response to targeted treatments such as PARP inhibitors.
Your doctor can explain whether you need further testing and whether your relatives may benefit from genetic counselling or earlier screening. Your results should always be considered alongside your cancer stage, family history and tumour testing to guide your care.
Myth vs Fact
| Myth | Fact |
| BRCA1 and BRCA2 are the only inherited prostate-cancer genes. | Several other genes, including HOXB13, ATM, CHEK2 and MSH2, have evidence of association. |
| Every prostate-cancer risk gene has the same effect. | Risk, aggressiveness and treatment relevance differ substantially by gene. |
| HOXB13 works like BRCA2. | HOXB13 is mainly a susceptibility gene and is not an HRR treatment biomarker. |
| HOXB13 G84E guarantees aggressive prostate cancer. | It raises cancer risk, but recent large data do not show clearly more aggressive tumours once cancer develops. |
| ATM means PARP inhibitors will work. | Current evidence shows substantially weaker benefit than in BRCA-altered disease. |
| CHEK2 is equivalent to BRCA2 for PARP treatment. | No. Treatment evidence is much weaker. |
| Every Lynch-syndrome prostate cancer is dMMR. | Tumour MMR status varies by gene and must be tested. |
| dMMR prostate cancer automatically qualifies for NHS pembrolizumab. | Current NICE MSI-H/dMMR pembrolizumab guidance does not routinely include prostate cancer. |
| HOXB13 is routinely tested on the NHS R430 panel. | It is not currently listed on the standard R430 panel. |
| More genes on a test always means a better test. | Broader panels can generate uncertain findings that may not change care. |
Key Takeaways
- HOXB13 is a genuine inherited prostate-cancer susceptibility gene, particularly the G84E variant.
- A 2025 study of more than 592,000 men found approximately a 3.17-fold higher prostate-cancer hazard in HOXB13 G84E carriers.
- HOXB13 appears to increase the likelihood of developing prostate cancer more clearly than it predicts aggressive tumour behaviour.
- HOXB13 is not currently part of the standard NHS England R430 panel.
- BRCA2 and ATM have stronger evidence linking pathogenic germline variants to aggressive prostate cancer.
- CHEK2 is associated with increased prostate-cancer risk, but its treatment implications are less established.
- PARP-inhibitor benefit varies substantially by gene; BRCA-altered cancers show the strongest evidence.
- ATM and CHEK2 should not be treated as equivalent to BRCA2 for PARP selection.
- Lynch syndrome can increase prostate-cancer risk, particularly in some MSH2/EPCAM and MSH6 families.
Frequently Asked Questions
1. What is HOXB13, and how is it linked to prostate cancer?
HOXB13 is a gene involved in prostate development and function. Certain inherited variants, particularly G84E, can increase the risk of developing prostate cancer, especially in people with a family history of the disease.
2. How much does the HOXB13 G84E variant increase prostate cancer risk?
The HOXB13 G84E variant is associated with approximately three times the risk of prostate cancer compared with not carrying the variant. Individual risk can vary depending on family history, ancestry and other factors.
3. Does carrying a HOXB13 variant mean prostate cancer will be aggressive?
No. HOXB13 variants increase the risk of developing prostate cancer, but they do not necessarily mean the cancer will be aggressive. Your doctor will consider your genetic results alongside other clinical findings.
4. How are HOXB13 and BRCA2 different in prostate cancer?
HOXB13 is primarily associated with inherited prostate cancer susceptibility, while BRCA2 plays a role in DNA repair. BRCA2 alterations may also influence treatment options, including eligibility for certain targeted therapies.
5. Can ATM and CHEK2 variants increase prostate cancer risk?
Yes. Certain inherited variants in ATM and CHEK2 can increase prostate cancer risk. The level of risk and potential treatment implications depend on the specific variant and your personal and family history.
6. Do ATM or CHEK2 variants mean PARP inhibitors will work?
No. Having an ATM or CHEK2 variant does not guarantee that PARP inhibitors will be effective. Their benefits are generally better established in prostate cancers with certain BRCA1 or BRCA2 alterations, and treatment decisions depend on the specific genetic findings and clinical circumstances.
7. How are Lynch syndrome genes such as MSH2 linked to prostate cancer?
Lynch syndrome results from inherited changes in DNA mismatch-repair genes, including MSH2, MSH6, MLH1 and PMS2. These changes increase the risk of several cancers, including prostate cancer, and may have implications for family screening and treatment.
8. Can inherited prostate cancer genes affect treatment options?
Yes. Certain genetic findings, such as BRCA1 or BRCA2 alterations, may help determine eligibility for targeted treatments. Tumours with mismatch-repair deficiency or high microsatellite instability may also be eligible for immunotherapy in specific clinical settings.
9. Should men with a strong family history of prostate cancer consider genetic testing?
Genetic testing may be appropriate for men with multiple relatives affected by prostate cancer, particularly at younger ages, or with a family history of related cancers. A doctor or genetic counsellor can help determine which genes should be tested.
10. What should family members do if an inherited prostate cancer risk variant is identified?
Biological relatives may consider genetic counselling and targeted testing for the specific inherited variant. If a pathogenic familial variant is confirmed, a healthcare professional can advise your male relatives about appropriate risk-based prostate assessment for their age, family history and gene.
Final Thoughts: Understanding Inherited Prostate Cancer Risk Genes
Inherited genes such as HOXB13, BRCA2, ATM, CHEK2 and MSH2 can influence your risk of developing prostate cancer, but each has different implications for screening, treatment and family health. Genetic testing can help clarify your individual risk, guide treatment decisions and identify whether your relatives may benefit from genetic counselling. Understanding your results with specialist guidance can help you make informed decisions about your care.
If you would like specialist advice about inherited prostate cancer risk or genetic testing, you can contact Prostate Clinic London to discuss whether further assessment may be appropriate for you.
References:
- NHS England (2026) National Genomic Test Directory. Available at:
https://www.england.nhs.uk/publication/national-genomic-test-directories/ - NHS England Genomics Education Programme (no date) Presentation: Patient with prostate cancer. GeNotes. Available at:
https://www.genomicseducation.hee.nhs.uk/genotes/in-the-clinic/presentation-patient-with-prostate-cancer/ - Crawford, T.B., Nelson, T., Karunamuni, R. et al. (2025) ‘Association of HOXB13 G84E With Prostate Cancer Among 592,158 Men’, Journal of the National Comprehensive Cancer Network, 23(10), e257055. Available at: https://pubmed.ncbi.nlm.nih.gov/40953603/
- Xu, J., Lu, J., Gielzak, M. et al. (2025) ‘Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines’, The Prostate, 85(12), pp. 1087–1095. Available at: https://pubmed.ncbi.nlm.nih.gov/40405569/
- Rodgers-Fouché, L., Kamkari, N.A., Cruz, M. et al. (2026) ‘Prostate Cancer Risk and DNA Mismatch Repair Deficiency Among Lynch Syndrome Patients’, European Urology Open Science, 83, pp. 83–90. Available at: https://pubmed.ncbi.nlm.nih.gov/41439160/
- Naqvi, S.A.A., Riaz, I.B., Bibi, A. et al. (2025) ‘Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis’, European Urology, 87(6), pp. 626–640. Available at: https://pubmed.ncbi.nlm.nih.gov/39848867/
- National Institute for Health and Care Excellence (2023) ‘Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency’. Technology appraisal guidance TA914. Available at: https://www.nice.org.uk/guidance/ta914